Trial
NCT05007769
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
Eli Lilly and Company; ImmunityBio, Inc.
Condition
Non-small Cell Lung Cancer
Intervention
Ramucirumab
Why stopped
Lost funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-05